Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.53 |
| ▸ | CDK4 | P11802 | 2/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.53 |
| ▸ | CCND1 | P24385 | 2/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.49 |
| ▸ | EGFR | P00533 | 8/20 | 0.47 |
| ▸ | CSF1R | P07333 | 7/20 | 0.47 |
| ▸ | WEE1 | P30291 | 1/20 | 0.45 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971306 | 0.92 | FGFR4 (0.53) | CDK1CDK4CCNB1CCND1CCNE1 | |
| SCHEMBL3968636 | 0.90 | EGFR (0.53) | CDK1CDK4CCNB1CCND1CCNE1 | |
| SCHEMBL3971767 | 0.88 | FGFR4 (0.62) | CDK1CDK4CCNB1CCND1CCNE1 | |
| SCHEMBL3968460 | 0.86 | CDK1 (0.45) | CDK1CDK4CCNB1CCND1CCNE1 | |
| SCHEMBL3976088 | 0.86 | FGFR4 (0.53) | CDK1CDK4CCNB1CCND1CCNE1 | |
| SCHEMBL3976274 | 0.81 | FGFR4 (0.48) | CDK4CCND1FGFR4FGFR1FGFR2 | |
| SCHEMBL3968497 | 0.79 | FGFR4 (0.52) | CDK1CDK4CCNB1CCND1CCNE1 | |
| SCHEMBL13593202 | 0.78 | FGFR4 (0.48) | FGFR4FGFR1FGFR2FGFR3BRD4 | |
| SCHEMBL3967144 | 0.78 | CDK1 (0.43) | CDK1CDK4CCNB1CCND1CCNE1 | |
| SCHEMBL3977883 | 0.77 | LCK (0.61) | CDK4CCND1FGFR4FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | claimed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | claimed |
| EP-1080092-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2001-03-07 | — | — | EP | claimed |
| WO-1999061444-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | claimed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | CDK1 11/4885CDK4 4/4885CCNB1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.